Arbutus Biopharma Corp, Inc. (NASDAQ:ABUS) Q1 2022 Earnings Conference Call May 5, 2022 8:45 AM ET

Company Participants

Lisa Caperelli - VP, IR

William Collier - President, CEO & Director

Michael Sofia - Chief Scientific Officer

David Hastings - CFO & CAO

Gaston Picchio - Chief Development Officer

Conference Call Participants

Douglas Buchanan - JMP Securities

Yuchen Ding - Jefferies

Thomas Yip - H.C. Wainwright & Co.

Luke Herrmann - Robert W. Baird & Co.

Keay Nakae - Chardan Capital Markets

Operator

Good day, and thank you for standing by. Welcome to the Arbutus Biopharma 2022 First Quarter Financial Results and Corporate Update Conference Call. [Operator Instructions].

I would now like to hand the conference over to your first speaker today, Lisa Caperelli, Vice President of Investor Relations. Thank you, and please go ahead.

Lisa Caperelli

Thank you, operator. Good morning, everyone, and thank you for joining Arbutus' first quarter 2022 Financial Results and Corporate Update Call. Joining me today from the Arbutus executive team are Bill Collier, President and Chief Executive Officer; David Hastings, Chief Financial Officer; Dr. Gaston Picchio, Chief Development Officer; and Dr. Mike Sofia, Chief Scientific Officer. Bill will begin with a corporate update, followed by Dr. Sofia, who will provide an update on our preclinical programs. Dave Hastings will then provide a review of the company's first quarter 2022 financial results. After opening remarks, we will open the call up for Q&A. Gaston Picchio will be available to address clinical-related questions.

Before we begin, we'd like to remind you that some of the statements made during the call today are forward-looking statements, which are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in our most recent annual report on 10-K, quarterly report on Form 10-Q to be filed later today and from time to time in other documents filed with the SEC.

I will now turn the call over to Bill. Bill?

William Collier

Thank you, Lisa, and good morning, everybody. Thank you for joining us. We appreciate your continued interest and support in Arbutus Biopharma.

As you saw in this morning's press release with our first quarter 2022 financial and corporate update, we are on track to deliver on multiple key milestones across our chronic hepatitis B and coronavirus programs. In fact, we anticipate reporting data from 4 clinical trials that are evaluating either 729 or 836 during this year. And importantly, as Dave will discuss later in this call, we are well positioned financially with a projected cash runway into the second quarter of 2024.